Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin PK with XELOX or FOLFOX-4 in Metastatic Colorectal Cancer
NCT00349336Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2006
- Primary completion
- Nov 2008
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Roche. Primary endpoint: Weekly Steady-state Exposure of Bevacizumab up to 48 weeks. Started Aug 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00349336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349336.